Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05054374 · ClinicalTrials.gov registry record · Phase 1
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05054374: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05054374 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05054374, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations. Researchers will look at whether mirdametinib on its own or in combination with the drug fulvestrant is a safe treatment that causes few or mild side effects in people with advanced solid tumor cancer.
Interventions
- DRUG Fulvestrant
- DRUG Mirdametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2023-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05054374
The ClinicalTrials.gov registry entry for NCT05054374 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT05054374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05054374 about?
NCT05054374 is a clinical study titled "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer". The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations. Researchers will look at whether mirdametinib on its own or in combination with the drug fulvestrant is a safe treatment that causes few or mild side...
What is the current status of trial NCT05054374?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-09-14. Estimated completion is 2023-10-26.
What interventions are being tested in trial NCT05054374?
The interventions under investigation include: Fulvestrant (DRUG), Mirdametinib (DRUG).
Who is sponsoring clinical trial NCT05054374?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.